The Priority Review

Clinical trials

Asundexian after stroke: 384 of 6,162 had an ischemic stroke versus 518 of 6,165 on placebo

In the 12,327-participant OCEANIC-STROKE trial, 384 of 6,162 on asundexian had an ischemic stroke versus 518 of 6,165 on placebo; ISTH major bleeding occurred in 117 versus 107. The record gives sites and sponsors the full Phase 3 numbers.

Machine-summarized from the primary sources listed below; not independently reported. How we use automation

Ischemic stroke occurred in 384 of 6,162 participants on asundexian and in 518 of 6,165 on placebo (hazard ratio 0.739, 95% confidence interval 0.647 to 0.843, p<0.0001) in the 12,327-participant Phase 3 OCEANIC-STROKE trial of people who had an acute non-cardioembolic ischemic stroke or a high-risk transient ischemic attack within the previous 72 hours, the study record shows. ISTH major bleeding, the trial's other primary outcome, occurred in 117 of 6,124 participants on asundexian and 107 of 6,130 on placebo (hazard ratio 1.104, 95% confidence interval 0.849 to 1.435, p=0.4587). Bayer sponsored the trial, and asundexian now has FDA-approved prescribing information under the name Sunharbo, indicated in combination with antiplatelet therapy to reduce the risk of stroke in adults with recent non-cardioembolic ischemic stroke (NIH Stroke Scale ≤15) or high-risk transient ischemic attack, the label states.

Hazard ratio by outcome Primary and secondary outcomes in OCEANIC-STROKE 0.4 0.6 0.8 1.0 1.2 1.4 1.6 Hazard ratio, asundexian versus placebo, with 95% confidence interval Ischemic stroke (primary outcome) 384 versus 518 participants 0.647 to 0.843 0.739 ISTH major bleeding (primary outcome) 117 versus 107 participants 0.849 to 1.435 1.104 All stroke, ischemic or hemorrhagic 404 versus 545 participants 0.649 to 0.840 0.738 Composite outcome 568 versus 685 participants 0.740 to 0.924 0.827 Disabling stroke (mRS ≥3 at 90 days) 128 versus 185 participants 0.553 to 0.867 0.692 All-cause mortality 248 versus 253 participants 0.826 to 1.173 0.984 Counts are participants with a first event in the full analysis set (6,162 asundexian, 6,165 placebo) unless noted. ISTH major bleeding was counted in the safety analysis set of 6,124 and 6,130. Composite outcome: composite of cardiovascular death, myocardial infarction or stroke. From the trial registry record NCT05686070, results first posted 2026-11-20. The Priority Review.
Hazard ratio by outcome Primary and secondary outcomes in OCEANIC-STROKE 0.4 0.6 0.8 1.0 1.2 1.4 1.6 Hazard ratio, asundexian versus placebo, with 95% confidence interval Ischemic stroke (primary outcome) 384 versus 518 participants 0.647 to 0.843 0.739 ISTH major bleeding (primary outcome) 117 versus 107 participants 0.849 to 1.435 1.104 All stroke, ischemic or hemorrhagic 404 versus 545 participants 0.649 to 0.840 0.738 Composite outcome 568 versus 685 participants 0.740 to 0.924 0.827 Disabling stroke (mRS ≥3 at 90 days) 128 versus 185 participants 0.553 to 0.867 0.692 All-cause mortality 248 versus 253 participants 0.826 to 1.173 0.984 Counts are participants with a first event in the full analysis set (6,162 asundexian, 6,165 placebo) unless noted. ISTH major bleeding was counted in the safety analysis set of 6,124 and 6,130. Composite outcome: composite of cardiovascular death, myocardial infarction or stroke. From the trial registry record NCT05686070, results first posted 2026-11-20. The Priority Review.

Why it matters

Sunharbo (asundexian) is a factor XIa inhibitor indicated in combination with antiplatelet therapy to reduce the risk of stroke in adults with recent non-cardioembolic ischemic stroke (NIH Stroke Scale ≤15) or high-risk transient ischemic attack, its label states. The study record says the trial set out to learn whether asundexian reduces ischemic strokes more than placebo when given in addition to standard antiplatelet therapy, and to compare major bleeding events between the two groups. Antiplatelet therapy is the current standard of care for people who have had a non-cardioembolic stroke, the record's summary states, because people who have had one face a higher risk of another stroke. The record also lists two published analyses of the trial: "Asundexian for Secondary Stroke Prevention" in N Engl J Med (2026 Apr 16) and a bleeding analysis in Circulation (2026 Oct 13).

Primary and secondary outcomes

Results were first posted 2026-11-20, the study record shows. The measures run up to 32 months of follow-up, and counts are participants with a first event in the full analysis set (6,162 asundexian, 6,165 placebo) unless noted.

  • Ischemic stroke (primary outcome): 384 versus 518 participants; hazard ratio 0.739 (95% confidence interval 0.647 to 0.843); p<0.0001
  • ISTH major bleeding (primary outcome, safety analysis set of 6,124 and 6,130): 117 versus 107 participants; hazard ratio 1.104 (95% confidence interval 0.849 to 1.435); p=0.4587
  • All stroke, ischemic or hemorrhagic: 404 versus 545 participants; hazard ratio 0.738 (95% confidence interval 0.649 to 0.840)
  • Composite of cardiovascular death, myocardial infarction or stroke: 568 versus 685 participants; hazard ratio 0.827 (95% confidence interval 0.740 to 0.924)
  • Disabling stroke (mRS ≥3 at 90 days): 128 versus 185 participants; hazard ratio 0.692 (95% confidence interval 0.553 to 0.867)
  • All-cause mortality: 248 versus 253 participants; hazard ratio 0.984 (95% confidence interval 0.826 to 1.173)

Trial design and participants

Participants on the drug took one daily oral dose of asundexian 50mg in combination with antiplatelet therapy; those on placebo took a matching daily tablet on the same background care, the record states. Mean age was 67.6 years (standard deviation 10.8), with 8,217 men and 4,110 women. Of the 12,327 randomized, 12,254 took the study intervention and 12,243 completed the study; of the 84 who did not complete, the record names withdrawal of consent or lost to follow up as the primary reason. The trial ran at 700 study centers in Asia, Europe, North America, South America, Australia and Israel between 26-Jan-2023 and 23-Oct-2025.

Bleeding and safety measures

Clinically relevant non-major bleeding occurred in 231 of 6,124 participants on asundexian versus 210 of 6,130 on placebo (hazard ratio 1.112, 95% confidence interval 0.923 to 1.341), and the composite of ISTH major or clinically relevant non-major bleeding in 339 versus 307 (hazard ratio 1.118, 95% confidence interval 0.958 to 1.305). Symptomatic intracranial hemorrhage occurred in 41 versus 36 participants (hazard ratio 1.151, 95% confidence interval 0.736 to 1.801), and hemorrhagic stroke in 13 versus 20. Serious adverse events were reported for 1,177 of 6,124 participants on asundexian and 1,196 of 6,130 on placebo, other adverse events for 2,600 and 2,667, and deaths for 248 of 6,162 and 253 of 6,165; the record notes its adverse event reporting for deaths excludes cardiovascular death, as exempted by protocol.

What remains uncertain

The safety and effectiveness of Sunharbo have not been established in pediatric patients, the label states.

Sources